Treating gynecologic malignancies with selective estrogen receptor downregulators (SERDs): Promise and challenges

Molecular and Cellular Endocrinology

Volumn 418, Issue , 2015, Pages 322-333

  Boisen, Michelle M ^a   Andersen, Courtney L ^b   Sreekumar, Sreeja ^b   Stern, Andrew M ^b   Oesterreich, Steffi ^c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

Endometrial carcinoma; Estrogen receptor; Ovarian carcinoma; Selective estrogen receptor downregulators (SERDs)

Indexed keywords

ARN 810; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ANTAGONIST; FULVESTRANT; PACLITAXEL; PROGESTERONE DERIVATIVE; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR DOWNREGULATOR; TAMOXIFEN; UNCLASSIFIED DRUG; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADVANCED CANCER; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL PROLIFERATION; DRUG EFFICACY; ENDOMETRIUM CANCER; HORMONE ACTION; HUMAN; META ANALYSIS (TOPIC); MONOTHERAPY; NONHUMAN; OVARIAN TISSUE; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG RESISTANCE; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; OVARIAN NEOPLASMS; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84949625723     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.04.035     Document Type: Article

References (178)

1. Addo S., Yates R.A., Laight A. A phase I trial to assess the pharmacology of the new oestrogen receptor antagonist fulvestrant on the endometrium in healthy postmenopausal volunteers. Br. J. Cancer 2002, 87:1354-1359.
2. Ahlgren J.D., Ellison N.M., Gottlieb R.J., Laluna F., Lokich J.J., Sinclair P.R., Ueno W., Wampler G.L., Yeung K.Y., Alt D., et al. Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1993, 11:1957-1968.
3. Alarid E.T., Bakopoulos N., Solodin N. Proteasome-mediated proteolysis of estrogen receptor: a novel component in autologous down-regulation. Mol. Endocrinol. 1999, 13:1522-1534.
4. Alarid E.T., Preisler-Mashek M.T., Solodin N.M. Thyroid hormone is an inhibitor of estrogen-induced degradation of estrogen receptor-α protein: estrogen-dependent proteolysis is not essential for receptor transactivation function in the pituitary. Endocrinology 2003, 144:3469-3476.
5. Anderson G.L., Judd H.L., Kaunitz A.M., Barad D.H., Beresford S.A., Pettinger M., Liu J., McNeeley S.G., Lopez A.M. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. Jama 2003, 290:1739-1748.
6. Argenta P.A., Thomas S.G., Judson P.L., Downs L.S., Geller M.A., Carson L.F., Jonson A.L., Ghebre R. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol. Oncol. 2009, 113:205-209.
7. Argenta P.A., Um I., Kay C., Harrison D., Faratian D., Sueblinvong T., Geller M.A., Langdon S.P. Predicting response to the anti-estrogen fulvestrant in recurrent ovarian cancer. Gynecol. Oncol. 2013, 131:368-373.
8. Badia E., Docquier A., Busson M., Lapierre M., Pujol P., Balaguer P., Cavailles V. Long-term treatment with the pure anti-estrogen fulvestrant durably remodels estrogen signaling in BG-1 ovarian cancer cells. J. Steroid Biochem. Mol. Biol. 2012, 132:176-185.
9. Beral V., Bull D., Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005, 365:1543-1551.
10. Beral V., Doll R., Hermon C., Peto R., Reeves G. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. Lancet 2008, 371:303-314.
11. Beresford S.A., Weiss N.S., Voigt L.F., McKnight B. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997, 349:458-461.
12. Berstein L.M., Tchernobrovkina A.E., Gamajunova V.B., Kovalevskij A.J., Vasilyev D.A., Chepik O.F., Turkevitch E.A., Tsyrlina E.V., Maximov S.J., Ashrafian L.A., Thijssen J.H. Tumor estrogen content and clinico-morphological and endocrine features of endometrial cancer. J. Cancer Res. Clin. Oncol. 2003, 129:245-249.
13. Block M., Fister S., Emons G., Seeber S., Grundker C., Gunthert A.R. Antiproliferative effects of antiestrogens and inhibitors of growth factor receptor signaling on endometrial cancer cells. Anticancer Res. 2010, 30:2025-2031.
14. Boehme K., Simon S., Mueller S.O. Gene expression profiling in Ishikawa cells: a fingerprint for estrogen active compounds. Toxicol. Appl. Pharmacol. 2009, 236:85-96.
15. Bokhman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol. Oncol. 1983, 15:10-17.
16. Boohyeong B., Yunhwa J. Repression of transcriptional activity of estrogen receptor alpha by a Cullin3/SPOP ubiquitin E3 ligase complex. Mol. Cells 2008, 25:289-293.
17. Bossard C., Busson M., Vindrieux D., Gaudin F., Machelon V., Brigitte M., Jacquard C., Pillon A., Balaguer P., Balabanian K., Lazennec G. Potential role of estrogen receptor beta as a tumor suppressor of epithelial ovarian cancer. PLoS One 2012, 7:e44787.
18. Bowman A., Gabra H., Langdon S.P., Lessells A., Stewart M., Young A., Smyth J.F. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2002, 8:2233-2239.
19. Brinton L.A., Berman M.L., Mortel R., Twiggs L.B., Barrett R.J., Wilbanks G.D., Lannom L., Hoover R.N. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am. J. Obstet. Gynecol. 1992, 167:1317-1325.
20. Brinton L.A., Felix A.S., McMeekin D.S., Creasman W.T., Sherman M.E., Mutch D., Cohn D.E., Walker J.L., Moore R.G., Downs L.S., Soslow R.A., Zaino R. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol. Oncol. 2013, 129:277-284.
21. Calligé M., Kieffer I., Richard-Foy H. CSN5/Jab1 is involved in ligand-dependent degradation of estrogen receptor α by the proteasome. Mol. Cell. Biol. 2005, 25:4349-4358.
22. Cavalieri E.L., Rogan E.G. Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer. J. Steroid Biochem. Mol. Biol. 2011, 125:169-180.
23. Chang C.Y., McDonnell D.P. Molecular pathways: the metabolic regulator estrogen-related receptor alpha as a therapeutic target in cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2012, 18:6089-6095.
24. Ciruelos Gil E.M. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer. Cancer Treat. Rev. 2014, 40:862-871.
25. Collaborative Group On Epidemiological Studies Of Ovarian C Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015.
26. Couse J.F., Korach K.S. Estrogen receptor null mice: what have we learned and where will they lead us?. Endocr. Rev. 1999, 20:358-417.
27. Covens A.L., Filiaci V., Gersell D., Lutman C.V., Bonebrake A., Lee Y.C. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 2011, 120:185-188.
28. Crowder R.J., Phommaly C., Tao Y., Hoog J., Luo J., Perou C.M., Parker J.S., Miller M.A., Huntsman D.G., Lin L., Snider J., Davies S.R., Olson J.A., Watson M.A., Saporita A., Weber J.D., Ellis M.J. PIK3CA and PIK3CB inhibition produce synthetic lethality when combined with estrogen deprivation in estrogen receptor-positive breast cancer. Cancer Res. 2009, 69:3955-3962.
29. Dauvois S., Danielian P.S., White R., Parker M.G., Antiestrogen I.C.I. 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:4037-4041.
30. Dauvois S., White R., Parker M.G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J. Cell Sci. 1993, 106(Pt 4):1377-1388.
31. del Carmen M.G., Fuller A.F., Matulonis U., Horick N.K., Goodman A., Duska L.R., Penson R., Campos S., Roche M., Seiden M.V. Phase II trial of anastrozole in women with asymptomatic mullerian cancer. Gynecol. Oncol. 2003, 91:596-602.
32. Delaunay F., Pettersson K., Tujague M., Gustafsson J.A. Functional differences between the amino-terminal domains of estrogen receptors alpha and beta. Mol. Pharmacol. 2000, 58:584-590.
33. Dennis A.P., Haq R.U., Nawaz Z. Importance of the regulation of nuclear receptor degradation. Front. Biosci. A J. Virtual Libr. 2001, 6:D954-D959.
34. Di Leo A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R., Verhoeven D., Pedrini J.L., Smirnova I., Lichinitser M.R., Pendergrass K., Garnett S., Lindemann J.P., Sapunar F., Martin M. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2010, 28:4594-4600.
35. Di Leo A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R., Verhoeven D., Pedrini J.L., Smirnova I., Lichinitser M.R., Pendergrass K., Malorni L., Garnett S., Rukazenkov Y., Martin M. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J. Natl. Cancer Inst. 2014, 106:djt337.
36. Diep C.H., Charles N.J., Gilks C.B., Kalloger S.E., Argenta P.A., Lange C.A. Progesterone receptors induce FOXO1-dependent senescence in ovarian cancer cells. Cell Cycle 2013, 12:1433-1449.
37. Duong V., Boulle N., Daujat S., Chauvet J., Bonnet S., Neel H., Cavailles V. Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res. 2007, 67:5513-5521.
38. DuSell C.D., Umetani M., Shaul P.W., Mangelsdorf D.J., McDonnell D.P. 27-hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol. Endocrinol. 2008, 22:65-77.
39. Eakin C.M., MacCoss M.J., Finney G.L., Klevit R.E. Estrogen receptor α is a putative substrate for the BRCA1 ubiquitin ligase. Proc. Natl. Acad. Sci. 2007, 104:5794-5799.
40. Emons G., Gunthert A., Thiel F.C., Camara O., Strauss H.G., Breitbach G.P., Kolbl H., Reimer T., Finas D., Rensing K. Phase II study of fulvestrant 250 mg/month in patients with recurrent or metastatic endometrial cancer: a study of the Arbeitsgemeinschaft Gynakologische Onkologie. Gynecol. Oncol. 2013, 129:495-499.
41. Eritja N., Domingo M., Dosil M.A., Mirantes C., Santacana M., Valls J., Llombart-Cussac A., Matias-Guiu X., Dolcet X. Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells. Mol. Cancer Ther. 2014, 13:776-787.
42. Fan M., Bigsby R.M., Nephew K.P. The NEDD8 pathway is required for proteasome-mediated degradation of human estrogen receptor (ER)-α and essential for the antiproliferative activity of ICI 182,780 in ERα-positive breast cancer cells. Mol. Endocrinol. 2003, 17:356-365.
43. Fan M., Yan P.S., Hartman-Frey C., Chen L., Paik H., Oyer S.L., Salisbury J.D., Cheng A.S., Li L., Abbosh P.H., Huang T.H., Nephew K.P. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 2006, 66:11954-11966.
44. Farnell Y.Z., Ing N.H. The effects of estradiol and selective estrogen receptor modulators on gene expression and messenger RNA stability in immortalized sheep endometrial stromal cells and human endometrial adenocarcinoma cells. J. Steroid Biochem. Mol. Biol. 2003, 84:453-461.
45. Felix A.S., Weissfeld J.L., Stone R.A., Bowser R., Chivukula M., Edwards R.P., Linkov F. Factors associated with Type I and Type II endometrial cancer. Cancer Causes Control CCC 2010, 21:1851-1856.
46. Filardo E.J., Quinn J.A., Bland K.I., Frackelton A.R. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. Mol. Endocrinol. 2000, 14:1649-1660.
47. Fiorica J.V., Brunetto V.L., Hanjani P., Lentz S.S., Mannel R., Andersen W. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 2004, 92:10-14.
48. Fox C. Exciting Gains in Fighting Breast Cancer Hormone-therapy Resistance 2014, Bioscience Technology Online, 2015(March 12), accessed 3.12.15. http://www.biosciencetechnology.com/articles/2014/11/exciting-gains-fighting-breast-cancer-hormone-therapy-resistance.
49. Fox E.M., Arteaga C.L., Miller T.W. Abrogating endocrine resistance by targeting ERalpha and PI3K in breast cancer. Front. Oncol. 2012, 2:145.
50. Frogne T., Jepsen J.S., Larsen S.S., Fog C.K., Brockdorff B.L., Lykkesfeldt A.E. Antiestrogen-resistant human breast cancer cells require activated protein kinase B/Akt for growth. Endocr.-Relat. Cancer 2005, 12:599-614.
51. Frogne T., Benjaminsen R.V., Sonne-Hansen K., Sorensen B.S., Nexo E., Laenkholm A.-V., Rasmussen L.M., Riese D.J., de Cremoux P., Stenvang J. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res. Treat. 2009, 114:263-275.
52. Gao M., Sun P.M., Wang J.L., Li X.P., Zhao C., Wei L.H. Different biological effect of estrogen receptor-related receptor alpha in estrogen receptor-positive and -negative endometrial carcinoma. Mol. Med. Rep. 2008, 1:917-924.
53. Garg P.P., Kerlikowske K., Subak L., Grady D. Hormone replacement therapy and the risk of epithelial ovarian carcinoma: a meta-analysis. Obstet. Gynecol. 1998, 92:472-479.
54. Gielen S.C., Burger C.W., Kuhne L.C., Hanifi-Moghaddam P., Blok L.J. Analysis of estrogen agonism and antagonism of tamoxifen, raloxifene, and ICI182780 in endometrial cancer cells: a putative role for the epidermal growth factor receptor ligand amphiregulin. J. Soc. Gynecol. Investig. 2005, 12:e55-67.
55. Group EBCTC, Davies C., Godwin J., Gray R., Clarke M., Cutter D., Darby S., McGale P., Pan H.C., Taylor C., Wang Y.C., Dowsett M., Ingle J., Peto R. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 2011, 378:771-784.
56. Gu Z., Lee R.Y., Skaar T.C., Bouker K.B., Welch J.N., Lu J., Liu A., Zhu Y., Davis N., Leonessa F. Association of interferon regulatory factor-1, nucleophosmin, nuclear factor-κB, and cyclic AMP response element binding with acquired resistance to Faslodex (ICI 182,780). Cancer Res. 2002, 62:3428-3437.
57. Guo R.X., Wei L.H., Zhao D., Wang J.L., Li X.P. Effects of ICI182780 (Faslodex) on proliferation and apoptosis induced by 17beta-estradiol in endometrial carcinoma cells. Beijing da xue xue bao Yi xue ban = J. Peking Univ. Health Sci. 2006, 38:470-474.
58. Hapangama D.K., Kamal A.M., Bulmer J.N. Estrogen receptor beta: the guardian of the endometrium. Hum. Reprod. Update 2015, 21:174-193.
59. Hatch K.D., Beecham J.B., Blessing J.A., Creasman W.T. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 1991, 68:269-271.
60. Havrilesky L.J., McMahon C.P., Lobenhofer E.K., Whitaker R., Marks J.R., Berchuck A. Relationship between expression of coactivators and corepressors of hormone receptors and resistance of ovarian cancers to growth regulation by steroid hormones. J. Soc. Gynecol. Investig. 2001, 8:104-113.
61. Hecht J.L., Mutter G.L. Molecular and pathologic aspects of endometrial carcinogenesis. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2006, 24:4783-4791.
62. Hou J.Y., Rodriguez-Gabin A., Samaweera L., Hazan R., Goldberg G.L., Horwitz S.B., McDaid H.M. Exploiting MEK inhibitor-mediated activation of ERalpha for therapeutic intervention in ER-positive ovarian carcinoma. PLoS One 2013, 8:e54103.
63. Howell A. Fulvestrant ('Faslodex'): current and future role in breast cancer management. Crit. Rev. Oncol./Hematol. 2006, 57:265-273.
64. Howell A., Osborne C.K., Morris C., Wakeling A.E. ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen. Cancer 2000, 89:817-825.
65. Howell A., Robertson J.F., Quaresma Albano J., Aschermannova A., Mauriac L., Kleeberg U.R., Vergote I., Erikstein B., Webster A., Morris C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2002, 20:3396-3403.
66. Huvila J., Talve L., Carpen O., Edqvist P.H., Ponten F., Grenman S., Auranen A. Progesterone receptor negativity is an independent risk factor for relapse in patients with early stage endometrioid endometrial adenocarcinoma. Gynecol. Oncol. 2013, 130:463-469.
67. Iqbal J., Ginsburg O.M., Wijeratne T.D., Howell A., Evans G., Sestak I., Narod S.A. Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: a systematic review. Cancer Treat. Rev. 2012, 38:318-328.
68. Ito K., Utsunomiya H., Yaegashi N., Sasano H. Biological roles of estrogen and progesterone in human endometrial carcinoma-new developments in potential endocrine therapy for endometrial cancer. Endocr. J. 2007, 54:667-679.
69. Jager W., Sauerbrei W., Beck E., Maassen V., Stumpfe M., Meier W., Kuhn W., Janicke F. A randomized comparison of triptorelin and tamoxifen as treatment of progressive ovarian cancer. Anticancer Res. 1995, 15:2639-2642.
70. Jeselsohn R., Yelensky R., Buchwalter G., Frampton G., Meric-Bernstam F., Gonzalez-Angulo A.M., Ferrer-Lozano J., Perez-Fidalgo J.A., Cristofanilli M., Gómez H. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin. Cancer Res. 2014, 20:1757-1767.
71. Jongen V., Briet J., de Jong R., ten Hoor K., Boezen M., van der Zee A., Nijman H., Hollema H. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer. Gynecol. Oncol. 2009, 112:537-542.
72. Kamitani T., Kito K., Nguyen H.P., Yeh E.T. Characterization of NEDD8, a developmentally down-regulated ubiquitin-like protein. J. Biol. Chem. 1997, 272:28557-28562.
73. Kelley K.M., Rowan B.G., Ratnam M. Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting. Cancer Res. 2003, 63:2820-2828.
74. Kim J.J., Chapman-Davis E. Role of progesterone in endometrial cancer. Semin. Reprod. Med. 2010, 28:81-90.
75. Kim J.J., Sefton E.C., Bulun S.E. Progesterone receptor action in leiomyoma and endometrial cancer. Prog. Mol. Biol. Transl. Sci. 2009, 87:53-85.
76. Klinge C.M. Estrogen receptor interaction with co-activators and co-repressors. Steroids 2000, 65:227-251.
77. Knudsen S., Jensen T., Hansen A., Mazin W., Lindemann J., Kuter I., Laing N., Anderson E. Development and validation of a gene expression score that predicts response to fulvestrant in breast cancer patients. PLoS One 2014, 9:e87415.
78. Kocanova S., Mazaheri M., Caze-Subra S., Bystricky K. Ligands specify estrogen receptor alpha nuclear localization and degradation. BMC Cell Biol. 2010, 11:98.
79. Korch C., Spillman M.A., Jackson T.A., Jacobsen B.M., Murphy S.K., Lessey B.A., Jordan V.C., Bradford A.P. DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol. Oncol. 2012, 127:241-248.
80. Kurose K., Zhou X.P., Araki T., Cannistra S.A., Maher E.R., Eng C. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas. Am. J. Pathol. 2001, 158:2097-2106.
81. Lam S.S., Mak A.S., Yam J.W., Cheung A.N., Ngan H.Y., Wong A.S. Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cells. Mol. Ther. J. Am. Soc. Gene Ther. 2014, 22:743-751.
82. Langdon S.P., Crew A.J., Ritchie A.A., Muir M., Wakeling A., Smyth J.F., Miller W.R. Growth inhibition of oestrogen receptor-positive human ovarian carcinoma by anti-oestrogens in vitro and in a xenograft model. Eur. J. Cancer 1994, 30A:682-686.
83. Lebeau A., Grob T., Holst F., Seyedi-Fazlollahi N., Moch H., Terracciano L., Turzynski A., Choschzick M., Sauter G., Simon R. Oestrogen receptor gene (ESR1) amplification is frequent in endometrial carcinoma and its precursor lesions. J. Pathol. 2008, 216:151-157.
84. Leblanc K., Sexton E., Parent S., Belanger G., Dery M.C., Boucher V., Asselin E. Effects of 4-hydroxytamoxifen, raloxifene and ICI 182 780 on survival of uterine cancer cell lines in the presence and absence of exogenous estrogens. Int. J. Oncol. 2007, 30:477-487.
85. Lentz S.S., Brady M.F., Major F.J., Reid G.C., Soper J.T. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1996, 14:357-361.
86. Li S., Shen D., Shao J., Crowder R., Liu W., Prat A., He X., Liu S., Hoog J., Lu C., Ding L., Griffith O.L., Miller C., Larson D., Fulton R.S., Harrison M., Mooney T., McMichael J.F., Luo J., Tao Y., Goncalves R., Schlosberg C., Hiken J.F., Saied L., Sanchez C., Giuntoli T., Bumb C., Cooper C., Kitchens R.T., Lin A., Phommaly C., Davies S.R., Zhang J., Kavuri M.S., McEachern D., Dong Y.Y., Ma C., Pluard T., Naughton M., Bose R., Suresh R., McDowell R., Michel L., Aft R., Gillanders W., DeSchryver K., Wilson R.K., Wang S., Mills G.B., Gonzalez-Angulo A., Edwards J.R., Maher C., Perou C.M., Mardis E.R., Ellis M.J. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013, 4:1116-1130.
87. Li L., Li X., Han X., Yang T., Fu J., Zhang Y., Gou W. An ovarian cancer model with positive ER: reversion of ER antagonist resistance by Src blockade. Oncol. Rep. 2014, 32:943-950.
88. Lokich E., Singh R.K., Han A., Romano N., Yano N., Kim K., Moore R.G. HE4 expression is associated with hormonal elements and mediated by importin-dependent nuclear translocation. Sci. Rep. 2014, 4:5500.
89. Long X., Nephew K.P. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-alpha. J. Biol. Chem. 2006, 281:9607-9615.
90. Lukanova A., Lundin E., Micheli A., Arslan A., Ferrari P., Rinaldi S., Krogh V., Lenner P., Shore R.E., Biessy C., Muti P., Riboli E., Koenig K.L., Levitz M., Stattin P., Berrino F., Hallmans G., Kaaks R., Toniolo P., Zeleniuch-Jacquotte A. Circulating levels of sex steroid hormones and risk of endometrial cancer in postmenopausal women. Int. J. Cancer J. Int. Cancer 2004, 108:425-432.
91. Ma B.B., Oza A., Eisenhauer E., Stanimir G., Carey M., Chapman W., Latta E., Sidhu K., Powers J., Walsh W., Fyles A. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers-a study of the National Cancer Institute of Canada Clinical Trials Group. Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 2004, 14:650-658.
92. Mabuchi S., Ohmichi M., Kimura A., Nishio Y., Arimoto-Ishida E., Yada-Hashimoto N., Tasaka K., Murata Y. Estrogen inhibits paclitaxel-induced apoptosis via the phosphorylation of apoptosis signal-regulating kinase 1 in human ovarian cancer cell lines. Endocrinology 2004, 145:49-58.
93. MacGregor J.I., Jordan V.C. Basic guide to the mechanisms of antiestrogen action. Pharmacol. Rev. 1998, 50:151-196.
94. Marsaud Vr, Gougelet Al, Maillard S., Renoir J.-M. Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous estrogen receptor α (ERα), differentially affect ERα extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells. Mol. Endocrinol. 2003, 17:2013-2027.
95. Matsumoto M., Yamaguchi Y., Seino Y., Hatakeyama A., Takei H., Niikura H., Ito K., Suzuki T., Sasano H., Yaegashi N., Hayashi S. Estrogen signaling ability in human endometrial cancer through the cancer-stromal interaction. Endocr.-Relat. cancer 2008, 15:451-463.
96. McClelland R.A., Barrow D., Madden T.A., Dutkowski C.M., Pamment J., Knowlden J.M., Gee J.M., Nicholson R.I. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex). Endocrinology 2001, 142:2776-2788.
97. Miller T.W., Hennessy B.T., Gonzalez-Angulo A.M., Fox E.M., Mills G.B., Chen H., Higham C., Garcia-Echeverria C., Shyr Y., Arteaga C.L. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J. Clin. Investig. 2010, 120:2406-2413.
98. Mueck A.O., Seeger H., Rabe T. Hormonal contraception and risk of endometrial cancer: a systematic review. Endocr.-Relat. cancer 2010, 17:R263-R271.
99. Mueller S.O., Korach K.S. Estrogen receptors and endocrine diseases: lessons from estrogen receptor knockout mice. Curr. Opin. Pharmacol. 2001, 1:613-619.
100. Mungenast F., Thalhammer T. Estrogen biosynthesis and action in ovarian cancer. Front. Endocrinol. 2014, 5:192.
101. Musgrove E.A. Estrogen receptor degradation: a CUE for endocrine resistance?. Breast Cancer Res. BCR 2011, 13:312.
102. Mutter G.L., Lin M.C., Fitzgerald J.T., Kum J.B., Baak J.P., Lees J.A., Weng L.P., Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J. Natl. Cancer Inst. 2000, 92:924-930.
103. Mutter G.L., Lin M.C., Fitzgerald J.T., Kum J.B., Eng C. Changes in endometrial PTEN expression throughout the human menstrual cycle. J. Clin. Endocrinol. Metab. 2000, 85:2334-2338.
104. Nawaz Z., Lonard D.M., Dennis A.P., Smith C.L., O'Malley B.W. Proteasome-dependent degradation of the human estrogen receptor. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:1858-1862.
105. Nicholson R., Hutcheson I., Hiscox S., Knowlden J., Giles M., Barrow D., Gee J. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer. Endocr.-Relat. Cancer 2005, 12:S29-S36.
106. Health NIo. A study of ARN-810 (GDC-0810) in postmenopausal women with Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer. Accessed 3/12, 2015. https://clinicaltrials.gov/ct2/show/NCT01823835.
107. Health NIo. A Global study to Compare the effects of Fulvestrant and Arimidex in a Subset of Patients with Breast Cancer. (FALCON). Accessed 3/12, 2015. https://clinicaltrials.gov/ct2/show/NCT01602380?term=falcon+breast+cancer&rank=1.
108. Normanno N., Di Maio M., De Maio E., De Luca A., de Matteis A., Giordano A., Perrone F., Group N.C.-N.B.C. Mechanisms of endocrine resistance and novel therapeutic strategies in breast cancer. Endocr. Relat. Cancer 2005, 12:721-747.
109. Nyholm H.C., Nielsen A.L., Lyndrup J., Dreisler A., Hagen C., Haug E. Plasma oestrogens in postmenopausal women with endometrial cancer. Br. J. Obstet. Gynaecol. 1993, 100:1115-1119.
110. O'Regan R.M., Cisneros A., England G.M., MacGregor J.I., Muenzner H.D., Assikis V.J., Bilimoria M.M., Piette M., Dragan Y.P., Pitot H.C., Chatterton R., Jordan V.C. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth. J. Natl. Cancer Inst. 1998, 90:1552-1558.
111. Oesterreich S., Brufsky A.M., Davidson N.E. Using mice to treat (wo)men: mining genetic changes in patient xenografts to attack breast cancer. Cell Rep. 2013, 4:1061-1062.
112. Ohtake F., Fujii-Kuriyama Y., Kato S. AhR acts as an E3 ubiquitin ligase to modulate steroid receptor functions. Biochem. Pharmacol. 2009, 77:474-484.
113. Olsen C.M., Green A.C., Whiteman D.C., Sadeghi S., Kolahdooz F., Webb P.M. Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur. J. Cancer 2007, 43:690-709.
114. Osborne R.J., Malik S.T., Slevin M.L., Harvey V.J., Spona J., Salzer H., Williams C.J. Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule. Br. J. Cancer 1988, 57:115-116.
115. Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S., Gertler S.Z., May J.T., Burton G., Dimery I., Webster A., Morris C., Elledge R., Buzdar A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2002, 20:3386-3395.
116. Pan X., Zhou T., Tai Y.H., Wang C., Zhao J., Cao Y., Chen Y., Zhang P.J., Yu M., Zhen C., Mu R., Bai Z.F., Li H.Y., Li A.L., Liang B., Jian Z., Zhang W.N., Man J.H., Gao Y.F., Gong W.L., Wei L.X., Zhang X.M. Elevated expression of CUEDC2 protein confers endocrine resistance in breast cancer. Nat. Med. 2011, 17:708-714.
117. Papadimitriou C.A., Markaki S., Siapkaras J., Vlachos G., Efstathiou E., Grimani I., Hamilos G., Zorzou M., Dimopoulos M.A. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study. Oncology 2004, 66:112-117.
118. Persson I., Adami H.O., Bergkvist L., Lindgren A., Pettersson B., Hoover R., Schairer C. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 1989, 298:147-151.
119. Petrie W.K., Dennis M.K., Hu C., Dai D., Arterburn J.B., Smith H.O., Hathaway H.J., Prossnitz E.R. G protein-coupled estrogen receptor-selective ligands modulate endometrial tumor growth. Obstet. Gynecol. Int. 2013, 2013:472720.
120. Pfoh R., Lacdao I.K., Saridakis V. Deubiquitinases and the new therapeutic opportunities offered to cancer. Endocr.-Relat. Cancer 2015, 22:T35-T54.
121. Pickart C.M. Mechanisms underlying ubiquitination. Annu. Rev. Biochem. 2001, 70:503-533.
122. Potischman N., Hoover R.N., Brinton L.A., Siiteri P., Dorgan J.F., Swanson C.A., Berman M.L., Mortel R., Twiggs L.B., Barrett R.J., Wilbanks G.D., Persky V., Lurain J.R. Case-control study of endogenous steroid hormones and endometrial cancer. J. Natl. Cancer Inst. 1996, 88:1127-1135.
123. Potischman N., Swanson C.A., Siiteri P., Hoover R.N. Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J. Natl. Cancer Inst. 1996, 88:756-758.
124. Ramirez P.T., Schmeler K.M., Milam M.R., Slomovitz B.M., Smith J.A., Kavanagh J.J., Deavers M., Levenback C., Coleman R.L., Gershenson D.M. Efficacy of letrozole in the treatment of recurrent platinum- and taxane-resistant high-grade cancer of the ovary or peritoneum. Gynecol. Oncol. 2008, 110:56-59.
125. Rao X., Di Leva G., Li M., Fang F., Devlin C., Hartman-Frey C., Burow M.E., Ivan M., Croce C.M., Nephew K.P. MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways. Oncogene 2011, 30:1082-1097.
126. Rendina G.M., Donadio C., Fabri M., Mazzoni P., Nazzicone P. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. Eur. J. Obstet., Gynecol. Reprod. Biol. 1984, 17:285-291.
127. Renehan A.G., Tyson M., Egger M., Heller R.F., Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008, 371:569-578.
128. Robertson J.F., Come S.E., Jones S.E., Beex L., Kaufmann M., Makris A., Nortier J.W., Possinger K., Rutqvist L.E. Endocrine treatment options for advanced breast cancer-the role of fulvestrant. Eur. J. Cancer 2005, 41:346-356.
129. Robertson John FR., L-C A., Feltl David, Dewar John, Jasiowka Mark, Hewson Nicola, Rukazenkov Yuri, Ellis Matthew J. Fulvestrant 500mg versus anastrazole as first-line treatement for advanced breast cancer: overall survival from the phase II "first" study. San Antonio Breast Cancer Symposium 2014.
130. Robinson D.R., Wu Y.M., Vats P., Su F., Lonigro R.J., Cao X., Kalyana-Sundaram S., Wang R., Ning Y., Hodges L., Gursky A., Siddiqui J., Tomlins S.A., Roychowdhury S., Pienta K.J., Kim S.Y., Roberts J.S., Rae J.M., Van Poznak C.H., Hayes D.F., Chugh R., Kunju L.P., Talpaz M., Schott A.F., Chinnaiyan A.M. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat. Genet. 2013, 45:1446-1451.
131. Rose P.G., Brunetto V.L., VanLe L., Bell J., Walker J.L., Lee R.B. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 2000, 78:212-216.
132. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75:495-505.
133. Schointuch M.N., Gilliam T.P., Stine J.E., Han X., Zhou C., Gehrig P.A., Kim K., Bae-Jump V.L. Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer. Gynecol. Oncol. 2014, 134:346-355.
134. Schwartz P.E., Keating G., MacLusky N., Naftolin F., Eisenfeld A. Tamoxifen therapy for advanced ovarian cancer. Obstet. Gynecol. 1982, 59:583-588.
135. Shabani N., Kuhn C., Kunze S., Schulze S., Mayr D., Dian D., Gingelmaier A., Schindlbeck C., Willgeroth F., Sommer H., Jeschke U., Friese K., Mylonas I. Prognostic significance of oestrogen receptor alpha (ERalpha) and beta (ERbeta), progesterone receptor A (PR-A) and B (PR-B) in endometrial carcinomas. Eur. J. Cancer 2007, 43:2434-2444.
136. Shah C.A., Lowe K.A., Paley P., Wallace E., Anderson G.L., McIntosh M.W., Andersen M.R., Scholler N., Bergan L.A., Thorpe J.D., Urban N., Drescher C.W. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol. Biomark. Prev. A Publ. Am. Assoc. Cancer Res. Cosponsored by Am. Soc. Prev. Oncol. 2009, 18:1365-1372.
137. Shang Y., Brown M. Molecular determinants for the tissue specificity of SERMs. Science 2002, 295:2465-2468.
138. Shirey D.R., Kavanagh J.J., Gershenson D.M., Freedman R.S., Copeland L.J., Jones L.A. Tamoxifen therapy of epithelial ovarian cancer. Obstet. Gynecol. 1985, 66:575-578.
139. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2015. CA A Cancer J. Clin. 2015, 65:5-29.
140. Sieh W., Kobel M., Longacre T.A., Bowtell D.D., deFazio A., Goodman M.T., Hogdall E., Deen S., Wentzensen N., Moysich K.B., Brenton J.D., Clarke B.A., Menon U., Gilks C.B., Kim A., Madore J., Fereday S., George J., Galletta L., Lurie G., Wilkens L.R., Carney M.E., Thompson P.J., Matsuno R.K., Kjaer S.K., Jensen A., Hogdall C., Kalli K.R., Fridley B.L., Keeney G.L., Vierkant R.A., Cunningham J.M., Brinton L.A., Yang H.P., Sherman M.E., Garcia-Closas M., Lissowska J., Odunsi K., Morrison C., Lele S., Bshara W., Sucheston L., Jimenez-Linan M., Driver K., Alsop J., Mack M., McGuire V., Rothstein J.H., Rosen B.P., Bernardini M.Q., Mackay H., Oza A., Wozniak E.L., Benjamin E., Gentry-Maharaj A., Gayther S.A., Tinker A.V., Prentice L.M., Chow C., Anglesio M.S., Johnatty S.E., Chenevix-Trench G., Whittemore A.S., Pharoah P.D., Goode E.L., Huntsman D.G., Ramus S.J. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013, 14:853-862.
141. Siiteri P.K. Adipose tissue as a source of hormones. Am. J. Clin. Nutr. 1987, 45:277-282.
142. Simard J., Sanchez R., Poirier D., Gauthier S., Singh S.M., Merand Y., Belanger A., Labrie C., Labrie F. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells. Cancer Res. 1997, 57:3494-3497.
143. Simpkins F., Hevia-Paez P., Sun J., Ullmer W., Gilbert C.A., da Silva T., Pedram A., Levin E.R., Reis I.M., Rabinovich B., Azzam D., Xu X.X., Ince T.A., Yang J.Y., Verhaak R.G., Lu Y., Mills G.B., Slingerland J.M. Src Inhibition with saracatinib reverses fulvestrant resistance in ER-positive ovarian cancer models in vitro and in vivo. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 2012, 18:5911-5923.
144. Singh M., Zaino R.J., Filiaci V.J., Leslie K.K. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 2007, 106:325-333.
145. Sinkevicius K.W., Burdette J.E., Woloszyn K., Hewitt S.C., Hamilton K., Sugg S.L., Temple K.A., Wondisford F.E., Korach K.S., Woodruff T.K., Greene G.L. An estrogen receptor-alpha knock-in mutation provides evidence of ligand-independent signaling and allows modulation of ligand-induced pathways in vivo. Endocrinology 2008, 149:2970-2979.
146. Slavik M., Petty W.M., Blessing J.A., Creasman W.T., Homesley H.D. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer Treat. Rep. 1984, 68:809-811.
147. Slevin M.L., Harvey V.J., Osborne R.J., Shepherd J.H., Williams C.J., Mead G.M. A phase II study of tamoxifen in ovarian cancer. Eur. J. Cancer Clin. Oncol. 1986, 22:309-312.
148. Stanisic V., Malovannaya A., Qin J., Lonard D.M., O'Malley B.W. OTU domain-containing ubiquitin aldehyde-binding protein 1 (OTUB1) deubiquitinates estrogen receptor (ER) alpha and affects ERalpha transcriptional activity. J. Biol. Chem. 2009, 284:16135-16145.
149. Stenoien D.L., Patel K., Mancini M.G., Dutertre M., Smith C.L., O'Malley B.W., Mancini M.A. FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent. Nat. Cell Biol. 2001, 3:15-23.
150. Suga S., Kato K., Ohgami T., Yamayoshi A., Adachi S., Asanoma K., Yamaguchi S., Arima T., Kinoshita K., Wake N. An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer. Gynecol. Oncol. 2007, 105:341-350.
151. Sun P., Sehouli J., Denkert C., Mustea A., Konsgen D., Koch I., Wei L., Lichtenegger W. Expression of estrogen receptor-related receptors, a subfamily of orphan nuclear receptors, as new tumor biomarkers in ovarian cancer cells. J. Mol. Med. Berl. 2005, 83:457-467.
152. Sun P.M., Wei L.H., Sehouli J., Denkert C., Zhao D., Gao M., Sun X.L., Litchtenegger W. Role of estrogen receptor-related receptors alpha, beta and gamma in ovarian cancer cells. Zhonghua fu chan ke za zhi 2005, 40:544-548.
153. Sun J., Zhou W., Kaliappan K., Nawaz Z., Slingerland J.M. ERalpha phosphorylation at Y537 by Src triggers E6-AP-ERalpha binding, ERalpha ubiquitylation, promoter occupancy, and target gene expression. Mol. Endocrinol. 2012, 26:1567-1577.
154. Sun J., Zhou W., Kaliappan K., Nawaz Z., Slingerland J.M. ERα phosphorylation at Y537 by Src triggers E6-AP-ERα binding, ERα ubiquitylation, promoter occupancy, and target gene expression. Mol. Endocrinol. 2012, 26:1567-1577.
155. Sun Y., Wang C., Yang H., Ma X. The effect of estrogen on the proliferation of endometrial cancer cells is mediated by ERRgamma through AKT and ERK1/2. Eur. J. Cancer Prev. 2014, 23:418-424.
156. Swenerton K.D. Treatment of advanced endometrial adenocarcinoma with tamoxifen. Cancer Treat. Rep. 1980, 64:805-811.
157. Swisher E.M., Peiffer-Schneider S., Mutch D.G., Herzog T.J., Rader J.S., Elbendary A., Goodfellow P.J. Differences in patterns of TP53 and KRAS2 mutations in a large series of endometrial carcinomas with or without microsatellite instability. Cancer 1999, 85:119-126.
158. Thigpen J.T., Brady M.F., Alvarez R.D., Adelson M.D., Homesley H.D., Manetta A., Soper J.T., Given F.T. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1999, 17:1736-1744.
159. Toy W., Shen Y., Won H., Green B., Sakr R.A., Will M., Li Z., Gala K., Fanning S., King T.A., Hudis C., Chen D., Taran T., Hortobagyi G., Greene G., Berger M., Baselga J., Chandarlapaty S. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. Nat. Genet. 2013, 45:1439-1445.
160. Trope C., Marth C., Kaern J. Tamoxifen in the treatment of recurrent ovarian carcinoma. Eur. J. Cancer 2000, 36(Suppl. 4):S59-S61.
161. Tsilidis K.K., Allen N.E., Key T.J., Dossus L., Lukanova A., Bakken K., Lund E., Fournier A., Overvad K., Hansen L., Tjonneland A., Fedirko V., Rinaldi S., Romieu I., Clavel-Chapelon F., Engel P., Kaaks R., Schutze M., Steffen A., Bamia C., Trichopoulou A., Zylis D., Masala G., Pala V., Galasso R., Tumino R., Sacerdote C., Bueno-de-Mesquita H.B., van Duijnhoven F.J., Braem M.G., Onland-Moret N.C., Gram I.T., Rodriguez L., Travier N., Sanchez M.J., Huerta J.M., Ardanaz E., Larranaga N., Jirstrom K., Manjer J., Idahl A., Ohlson N., Khaw K.T., Wareham N., Mouw T., Norat T., Riboli E. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into cancer and nutrition. Br. J. Cancer 2011, 105:1436-1442.
162. Van Der Velden J., Gitsch G., Wain G.V., Friedlander M.L., Hacker N.F. Tamoxifen in patients with advanced epithelial ovarian cancer. Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 1995, 5:301-305.
163. Wardell S.E., Marks J.R., McDonnell D.P. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy. Biochem. Pharmacol. 2011, 82:122-130.
164. Wei Y., Zhang Z., Liao H., Wu L., Wu X., Zhou D., Xi X., Zhu Y., Feng Y. Nuclear estrogen receptor-mediated Notch signaling and GPR30-mediated PI3K/AKT signaling in the regulation of endometrial cancer cell proliferation. Oncol. Rep. 2012, 27:504-510.
165. Weiderpass E., Adami H.O., Baron J.A., Magnusson C., Bergstrom R., Lindgren A., Correia N., Persson I. Risk of endometrial cancer following estrogen replacement with and without progestins. J. Natl. Cancer Inst. 1999, 91:1131-1137.
166. Weiner S.A., Alberts D.S., Surwit E.A., Davis J., Grosso D. Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol. Oncol. 1987, 27:208-213.
167. Wijayaratne A.L., McDonnell D.P. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J. Biol. Chem. 2001, 276:35684-35692.
168. Wijayaratne A.L., Nagel S.C., Paige L.A., Christensen D.J., Norris J.D., Fowlkes D.M., McDonnell D.P. Comparative analyses of mechanistic differences among antiestrogens 1. Endocrinology 1999, 140:5828-5840.
169. Woodruff J.D., Pickar J.H. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group. Am. J. Obstet. Gynecol. 1994, 170:1213-1223.
170. Yang S., Thiel K.W., Leslie K.K. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol. Metab. TEM 2011, 22:145-152.
171. Young R.H. Sex cord-stromal tumors of the ovary and testis: their similarities and differences with consideration of selected problems. Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc. 2005, 18(Suppl. 2):S81-S98.
172. Zeleniuch-Jacquotte A., Akhmedkhanov A., Kato I., Koenig K.L., Shore R.E., Kim M.Y., Levitz M., Mittal K.R., Raju U., Banerjee S., Toniolo P. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br. J. Cancer 2001, 84:975-981.
173. Zhang Y., Liao Q., Chen C., Yu L., Zhao J. Function of estrogen receptor isoforms alpha and beta in endometrial carcinoma cells. Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 2006, 16:1656-1660.
174. Zhang Q.G., Han D., Wang R.M., Dong Y., Yang F., Vadlamudi R.K., Brann D.W. C terminus of Hsc70-interacting protein (CHIP)-mediated degradation of hippocampal estrogen receptor-alpha and the critical period hypothesis of estrogen neuroprotection. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:E617-E624.
175. Zhao D., Zhang F., Zhang W., He J., Zhao Y., Sun J. Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc. 2013, 23:25-33.
176. Zhou W., Slingerland J.M. Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat. Rev. Cancer 2014, 14:26-38.
177. Zhou B., Sun Q., Cong R., Gu H., Tang N., Yang L., Wang B. Hormone replacement therapy and ovarian cancer risk: a meta-analysis. Gynecol. Oncol. 2008, 108:641-651.
178. Zhu X., Kwon C.H., Schlosshauer P.W., Ellenson L.H., Baker S.J. PTEN induces G(1) cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res. 2001, 61:4569-4575.